Biopticon

Founded in 2003, Biopticon specializes in creating advanced tools for preclinical cancer research, focusing on improving the accuracy and efficiency of tumor measurement and study management. Their flagship Tumor Management System, comprising the TumorImager-2 scanner and TumorManager software, is designed to replace traditional, less reliable caliper-based methods. The company collaborates with pharmaceutical partners like Bristol-Myers Squibb and leverages academic expertise from institutions such as Princeton University. Biopticon's mission is to provide researchers with superior data quality and workflow management in oncology drug development.

The Tumor Management System, an integrated hardware-software platform featuring the TumorImager-2™ 3D scanner for accurate tumor measurement in small animals and the TumorManager™ software for comprehensive preclinical study workflow management.

Total raised: $2.5M

Biopticon's main competitors are the entrenched manual caliper method (low cost) and large companies offering general-purpose preclinical imaging systems (high cost/complexity). Its differentiation lies in providing a specialized, integrated, and relatively affordable system that balances accuracy with usability for the specific workflow of tumor measurement and study management.